Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin and Exenatide for Weight Loss in Obese Non-diabetic Subjects
NCT02313220Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Dapagliflozin + Exenatide with Placebo (2 arms). Primary endpoint: Body weight (kg) at 24 weeks. Started Dec 2014; status: completed.
02
Drugs
dapagliflozinexenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02313220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02313220.